VivoSeq
Other

Hypoxemia

14

Pipeline Programs↗

5

Active Trials↗

8

Companies Involved↗

Hypoxemia is an emerging landscape with 14 programs across 8 companies. The most active players are Merck & Co., United Therapeutics, Scienture. 7 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

57/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1United Therapeutics logo

United Therapeutics

1 program

Phase 2S

Scienture

1 program

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3F

Fresenius Kabi Oncology Ltd.

2 programs

ApprovedAbbVie logo

AbbVie

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

18

clinical trials

Unknown status6 · 33%
Completed4 · 22%
Recruiting4 · 22%
Terminated2 · 11%
Withdrawn1 · 6%
Enrolling by invitation1 · 6%

Clinical Trials

Trial Activity

18 trials

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
Recruiting·—·Phase 2·NCT07037836·10 enrolled
Realist Evaluation and Learning in a Multi-country Medical OXYgen Program (REAL-MOXY)
Recruiting·MMurdoch Childrens Research Institute·N/A·NCT06087315·1,200 enrolled
Building Respiratory Support in East Africa Through High Flow Versus Standard Flow Oxygen Evaluation
Recruiting·BBeth Israel Deaconess Medical Center·Preclinical·NCT05754034·1,600 enrolled
Effect of Lateral Versus Supine Positions on Postoperative Hypoxemia in Patients Undergoing Painless Gastroscopy and Colonoscopy: A Prospective Randomized Controlled Study
Recruiting·GGeneral Hospital of Ningxia Medical University·Preclinical·NCT07545642·960 enrolled
Usefulness of High-flow Oxygen Therapy of Patients at Risk of Hypoxemia Undergoing Digestive Endoscopy Under Deep Sedation
Enrolling by invitation·OOutcomes'10·Phase 4·NCT07439822·326 enrolled
Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia
Completed·UUniversity of Missouri-Columbia·Phase 1·NCT05256069·31 enrolled
The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia
Completed·HHeidelberg University·Phase 2·NCT04207593·20 enrolled
Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia
Completed·IIstanbul University·Phase 2/3·NCT04990830·80 enrolled
Naloxone for Optimizing Hypoxemia Of Lung Donors
Completed·WWashington University School of Medicine·Phase 2/3·NCT02581111·199 enrolled
Consequences of Nocturnal and Daytime Hypoxemia in COPD
Terminated·NNorthwell Health·N/A·NCT00547456·20 enrolled
The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers
Terminated·IIndiana University·Phase 4·NCT05095311·16 enrolled
Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)
Withdrawn·Merck & Co. logoMerck & Co.·Phase 1·NCT04425733
Influence of Oxygen Target Range on Intermittent Hypoxemia in Preterm Infants
Unknown status·UUniversity of Ulm·N/A·NCT02743988·36 enrolled
Neuromuscular-Blocking Agents and Hypoxemia During Intubation in Infants (ROC-HYPOX)
Unknown status·FFondation Ophtalmologique Adolphe de Rothschild·Phase 4·NCT02589691·412 enrolled
Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit
Unknown status·UUniversity Hospital, Caen·N/A·NCT05155202·300 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)